Fibrin(ogen)olytic snake venom metalloproteases have been considered as potential drugs for treatment of vascular diseases.

Batroxase, a metalloprotease isolated from Bothrops atrox degrades components of the coagulation cascade as fibrinogen and fibrin.

Batroxase presented thrombolytic activity in vitro and in vivo.

Batroxase was inhibited by α2-macroglobulin decreasing the risk of bleeding complications due to its use.

These initial results suggests that Batroxase could possibly be used as a thrombolytic agent, effectively and safely.